Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership369,530 shares
Latest Disclosed Value $ 14,119,741
Barclays Plc ownership in TVTX / Travere Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 369,530 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $14,119,741 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 349,002 shares of Travere Therapeutics, Inc.. This represents a change in shares of 5.88% during the quarter. The current value of the position is $16,702,756 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (TVTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 212,000 of underlying shares valued at $8,100,520 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

TVTX / Travere Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 369,530 20,528 5.88 14,120 69.27 0.0034
2026-03-31 2025-09-30 13F/A-3 TRAVERE THERAPEUTICS COM 89422G107 349,002 -179,524 -33.97 8,341 6.64 0.0018
2026-03-19 2025-09-30 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 168,768 -359,758 2,361 0.0006
2025-11-12 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 349,002 -179,524 8,341 0.0018
2026-02-27 2025-06-30 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 528,526 -293,306 -35.69 7,822 -46.89 0.0018
2025-08-14 2025-06-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 528,526 -293,306 8 0.0018
2025-08-13 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 528,526 -293,306 8 0.0006
2026-03-17 2025-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 821,832 425,262 107.24 14,727 113.19 0.0042
2025-05-15 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 821,832 425,262 15 0.0042
2026-03-19 2024-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 396,570 227,802 134.98 6,908 192.59 0.0019
2025-02-13 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 396,570 227,802 7 0.0019
2026-03-31 2024-09-30 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 168,768 -17,544 -9.42 2,361 54.21 0.0006
2024-11-19 2024-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 168,768 -17,544 2 0.0006
2024-11-15 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 168,768 -17,544 2 0.0002
2026-03-23 2024-06-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 186,312 8,555 4.81 1,531 11.75 0.0005
2024-08-14 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 186,312 8,555 2 0.0005
2026-03-24 2024-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 177,757 -209,052 -54.05 1,371 -60.60 0.0005
2024-05-15 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 177,757 -209,052 1 0.0005
2026-03-25 2023-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 386,809 98,155 34.00 3,477 34.77 0.0013
2024-02-15 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 386,809 98,155 3 0.0013
2026-03-26 2023-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 288,654 36,071 14.28 2,581 -33.49 0.0016
2023-11-07 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 288,654 36,071 3 0.0016
2026-03-30 2023-06-30 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 252,583 49,797 24.56 3,880 -14.93 0.0025
2023-09-20 2023-06-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 252,583 49,797 4 0.0025
2023-08-03 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 252,583 49,797 4 0.0024
2026-03-30 2023-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 202,786 18,000 9.74 4,561 17.34 0.0021
2023-05-04 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 202,786 18,000 5 0.0021
2026-03-30 2022-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 184,786 47,873 34.97 3,886 15.17 0.0017
2023-02-13 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 184,786 47,873 4 0.0017
2022-11-03 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 136,913 111,357 435.74 3,374 445.07 0.0037
2022-08-12 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 25,556 -23,345 -47.74 619 -50.91 0.0004
2022-05-16 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 48,901 48,901 1,261 0.0010
2021-02-11 2020-12-31 13F RETROPHIN COM 761299106 0 -24,386 -100.00 0 -100.00
2020-11-12 2020-09-30 13F RETROPHIN COM 761299106 24,386 -14,606 -37.46 450 -43.47 0.0003
2020-08-12 2020-06-30 13F RETROPHIN COM 761299106 38,992 2,200 5.98 796 48.23 0.0006
2020-05-13 2020-03-31 13F RETROPHIN COM 761299106 36,792 -38,305 -51.01 537 -49.67 0.0004
2020-02-10 2019-12-31 13F RETROPHIN COM 761299106 75,097 45,744 155.84 1,067 212.90 0.0006
2019-11-15 2019-09-30 13F/A-1 RETROPHIN COM 761299106 29,353 -15,598 -34.70 341 -62.24 0.0002
2019-11-14 2019-09-30 13F RETROPHIN COM 761299106 29,353 -15,598 341 78.8396
2019-08-14 2019-06-30 13F RETROPHIN COM 761299106 44,951 25,175 127.30 903 102.01 0.0006
2019-05-15 2019-03-31 13F RETROPHIN COM 761299106 19,776 16,351 477.40 447 480.52 0.0003
2019-02-14 2018-12-31 13F RETROPHIN COM 761299106 3,425 -28,195 -89.17 77 -91.52 0.0001
2018-11-14 2018-09-30 13F RETROPHIN COM 761299106 31,620 23,585 293.53 908 312.73 0.0006
2018-08-14 2018-06-30 13F RETROPHIN COM 761299106 8,035 -12,154 -60.20 220 -51.11 0.0002
2018-05-15 2018-03-31 13F RETROPHIN COM 761299106 20,189 8,152 67.72 450 77.17 0.0003
2018-02-14 2017-12-31 13F RETROPHIN COM 761299106 12,037 -15,078 -55.61 254 -62.37 0.0002
2017-11-14 2017-09-30 13F RETROPHIN COM 761299106 27,115 24,943 1,148.39 675 1,507.14 0.0007
2017-08-14 2017-06-30 13F RETROPHIN COM 761299106 2,172 -7,620 -77.82 42 -76.67 0.0000
2017-05-15 2017-03-31 13F RETROPHIN COM 761299106 9,792 -8,649 -46.90 180 -48.42 0.0002
2017-02-14 2016-12-31 13F RETROPHIN COM 761299106 18,441 14,509 369.00 349 301.15 0.0004
2016-11-14 2016-09-30 13F RETROPHIN COM 761299106 3,932 3,833 3,871.72 87 4,250.00 0.0001
2016-08-12 2016-06-30 13F RETROPHIN COM 761299106 99 99 0.00 2 0.0000
2016-05-16 2016-03-31 13F RETROPHIN COM 761299106 0 -310,933 -100.00 0 -100.00
2016-02-12 2015-12-31 13F RETROPHIN COM 761299106 310,933 306,903 7,615.46 5,908 7,193.83 0.0072
2015-11-13 2015-09-30 13F RETROPHIN COM 761299106 4,030 -248 -5.80 81 -42.55 0.0001
2015-08-14 2015-06-30 13F RETROPHIN COM 761299106 4,278 3,306 340.12 141 540.91 0.0002
2015-05-19 2015-03-31 13F/A-1 RETROPHIN COM 761299106 972 -296 -23.34 22 37.50 0.0000
2015-05-14 2015-03-31 13F RETROPHIN COM 761299106 972 22
2015-02-13 2014-12-31 13F RETROPHIN COM 761299106 1,268 569 81.40 16 166.67 0.0000
2014-11-14 2014-09-30 13F RETROPHIN COM 761299106 699 78 12.56 6 -14.29 0.0000
2014-08-14 2014-06-30 13F RETROPHIN COM 761299106 621 102 19.65 7 -36.36 0.0000
2014-05-15 2014-03-31 13F RETROPHIN COM 761299106 519 519 11 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-03-31 2025-09-30 13F/A TRAVERE THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2026-03-19 2025-09-30 13F/A TRAVERE THERAPEUTICS OPT Call 0 0 n/a n/a n/a
2025-11-12 2025-09-30 13F TRAVERE THERAPEUTICS OPT Call 0 0 n/a n/a n/a
2025-08-14 2025-06-30 13F/A TRAVERE THERAPEUTICS OPT Call 30,000 0 n/a n/a n/a
2026-02-27 2025-06-30 13F/A TRAVERE THERAPEUTICS OPT Call 30,000 444 n/a n/a n/a
2026-03-24 2024-03-31 13F/A TRAVERE THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-05-15 2024-03-31 13F TRAVERE THERAPEUTICS OPT Call 0 0 n/a n/a n/a
2026-03-25 2023-12-31 13F/A TRAVERE THERAPEUTICS OPT Call 109,400 984 n/a n/a n/a
2024-02-15 2023-12-31 13F TRAVERE THERAPEUTICS OPT Call 109,400 1 n/a n/a n/a
2019-11-15 2019-09-30 13F/A RETROPHIN OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2019-08-14 2019-06-30 13F RETROPHIN OPT Call 100,000 2,009 n/a n/a n/a
2018-02-14 2017-12-31 13F RETROPHIN OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2017-11-14 2017-09-30 13F RETROPHIN OPT Call 144,200 144,100.00 3,589 179,350.00 n/a n/a n/a
2017-05-15 2017-03-31 13F RETROPHIN OPT Call 100 -83.33 2 -81.82 n/a n/a n/a
2017-02-14 2016-12-31 13F RETROPHIN OPT Call 600 11 n/a n/a n/a
2016-05-16 2016-03-31 13F RETROPHIN OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2016-02-12 2015-12-31 13F RETROPHIN OPT Call 155,800 54.56 2,960 46.83 n/a n/a n/a
2015-11-13 2015-09-30 13F RETROPHIN OPT Call 100,800 2,016 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-13 2025-12-31 13F TRAVERE THERAPEUTICS OPT Put 212,000 8,101 n/a n/a n/a
2026-03-23 2024-06-30 13F/A TRAVERE THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F TRAVERE THERAPEUTICS OPT Put 0 0 n/a n/a n/a
2026-03-24 2024-03-31 13F/A TRAVERE THERAPEUTICS OPT Put 112,000 -33.33 864 -42.85 n/a n/a n/a
2024-05-15 2024-03-31 13F TRAVERE THERAPEUTICS OPT Put 112,000 1 n/a n/a n/a
2026-03-25 2023-12-31 13F/A TRAVERE THERAPEUTICS OPT Put 168,000 1,510 n/a n/a n/a
2024-02-15 2023-12-31 13F TRAVERE THERAPEUTICS OPT Put 168,000 2 n/a n/a n/a
2019-11-15 2019-09-30 13F/A RETROPHIN OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2019-08-14 2019-06-30 13F RETROPHIN OPT Put 200 -80.00 4 -82.61 n/a n/a n/a
2019-05-15 2019-03-31 13F RETROPHIN OPT Put 1,000 -71.43 23 -70.89 n/a n/a n/a
2019-02-14 2018-12-31 13F RETROPHIN OPT Put 3,500 0.00 79 -21.78 n/a n/a n/a
2018-11-14 2018-09-30 13F RETROPHIN OPT Put 3,500 101 n/a n/a n/a
2016-05-16 2016-03-31 13F RETROPHIN OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2016-02-12 2015-12-31 13F RETROPHIN OPT Put 590,900 11,227 n/a n/a n/a
2015-11-13 2015-09-30 13F RETROPHIN OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2015-08-14 2015-06-30 13F RETROPHIN OPT Put 30,000 990 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.